www.clotprotect.comClotProtect are pioneering a new approach to tackle traumatic bleeding, with a first-in-class anti-fibrinolytic. ClotProtect are a therapeutics spin-out from the University of Leeds who are developing a novel small molecule anti-fibrinolytic to transform how acute bleeding is treated and safe lives. Led by world-leading experts from industry and academia, we’re pioneering a ground-breaking approach with immense therapeutic and commercial potential.

https://www.leanlifescience.comLean Life Science Oncology Development Programme is unique collaboration of 6 global pharmaceutical, 35 CROs and healthcare companies and research institutions, Cancer Research Horizons, InnovateUK, 2 cancer charities, 3 UK Catapults, he Christie NHS Foundation Trust, the Manchester Cancer Research Centre, 7 Life Science Member organisations, which leverages the combined insight and expertise of the partners for the ultimate benefit of patients.Through a disciplined and structured programme, its goal is to identify, de-risk and catalyse commercially viable ideas that improve the diagnosis and treatment of cancer, and vastly improve their likelihood of attracting future investment or collaborators in order to significantly increase their likelihood of commercial success. The approach helps successful innovations progress quickly into de-risked, investable propositions ready to meet patients’ needs.

www.nanoptima.comNanOptima is designing and developing innovative and safe intra-ocular depots so that a single injection can controllably release efficacious advanced therapies doses over 6-12 months to halt the progression of chronic, sight-threatening retinal diseasesWe are designing depots to ensure optical transparency, viscosity for fine-needle (30G) injection, immediate re-gelation inside the eye, and tuning rates of drug release over months to match depot biodegradation

Seed and Early Stage Life Science Investment Venture FundLead role in establishing Alderley Park Ventures (APV) investment fund at Alderley Park, and negotiating with AstraZeneca on its formationAdvisory board member

https://www.alderleypark.co.uk/oncologyprogrammeA unique collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight and expertise to nurture them into investment ready start-upsIts goal is to bring forward viable oncology projects much more quickly in order to significantly increase their likelihood of commercial successThe Oncology Development Programme aims to find and develop innovations that improve the diagnosis and treatment of cancerIts goal is to de-risk and catalyse commercially viable ideas, ready to take on new funding or collaborators in order to significantly increase their likelihood of commercial success. This approach will help successful innovations progress quickly into de-risked, investable propositions ready to meet patients’ needs.A collaboration of AstraZeneca, Johnson & Johnson Innovation, GlaxoSmithKline, Roche, The Christie NHS Foundation Trust, Medicines Discovery Catapult and the Manchester Cancer Research Centre will support researchers and start-ups aiming to develop their early-stage innovations. As delivery partner for the programme, Medicines Discovery Catapult, a national hub for research and development in drug discovery, will work closely with the selected participating researchers and start-ups, to help them develop fully validated, timed, costed, project plans with delivery partners in place, vastly improving their likelihood of attracting future investment.

https://www.alderleypark.co.uk/acceleratorAlderley Park Accelerator (formerly The BioHub), established 2013 to allow life science companies to take advantage of the world class facilities available at Alderley Park. Focused on attracting, creating, and scaling companies.• APA is a thriving ecosystem of life science companies, which has successfully counteracted the potential economic consequences (estimated at c£2bn over ten years) of AstraZeneca’s relocation of its largest R&D facility to Cambridge. • BioHub recognised by the "Outstanding Achievement" Award, the top award at the 2017 UK Life Science Industry OBN awards: “…the most novel and innovative company whose technology is causing significant disruption in their field.” • In both 2016 and 2017 achieved the "Best UK Life Science Incubator" for the BioHub because of “..the breadth and depth of the offering and complete support for companies…” The BioHub also received the 2015 Bionow “Best Service support” award. • World class Expert Mentoring Network, includes over 240 senior global industry leaders making themselves available to SME’s on site, subsequently expanded across the BioCity Group• Lean-start-up structured ‘bootcamps’ and programmes based upon international best practice, with content and advisory input from global thought leaders, now expanded across BioCity Group• Public and private strategic partnerships are established to provide pipeline services and support for on-site and national companies: NELSA, North of England Life Science Accelerator with the N8 Research Universities; Biofilm Innovation and Knowledge Centre; OBN discounted purchasing scheme, strategic partnership with Waters Corporation, corporate partnerships with professional service firms, and ELRIG• £3.2m in grants for Research, Innovation, and Business Support• Significant role in the regional and national life science ecosystem • Lead in establishing Alderley Park Ventures* Developed Alderley Park Oncology Prog

https://www.alderleypark.co.uk/acceleratorAlderley Park Accelerator (formerly The BioHub), established 2013 to allow life science companies to take advantage of the world class facilities available at Alderley Park. Focused on attracting, creating, and scaling companies.• APA is a thriving ecosystem of life science companies, which has successfully counteracted the potential economic consequences (estimated at c£2bn over ten years) of AstraZeneca’s relocation of its largest R&D facility to Cambridge. • BioHub recognised by the "Outstanding Achievement" Award, the top award at the 2017 UK Life Science Industry OBN awards: “…the most novel and innovative company whose technology is causing significant disruption in their field.” • In both 2016 and 2017 achieved the "Best UK Life Science Incubator" for the BioHub because of “..the breadth and depth of the offering and complete support for companies…” The BioHub also received the 2015 Bionow “Best Service support” award. • World class Expert Mentoring Network, includes over 240 senior global industry leaders making themselves available to SME’s on site, subsequently expanded across the BioCity Group• Lean-start-up structured ‘bootcamps’ and programmes based upon international best practice, with content and advisory input from global thought leaders, now expanded across BioCity Group• Public and private strategic partnerships are established to provide pipeline services and support for on-site and national companies: NELSA, North of England Life Science Accelerator with the N8 Research Universities; Biofilm Innovation and Knowledge Centre; OBN discounted purchasing scheme, strategic partnership with Waters Corporation, corporate partnerships with professional service firms, and ELRIG• £3.2m in grants for Research, Innovation, and Business Support• Significant role in the regional and national life science ecosystem • Lead in establishing Alderley Park Ventures (below)

Investment Banking, Private Placement (raising funds: pitch prep & introductions to investors) for venture and private equity investment in life science and technology companies and funds (both closed and open ended)

BioHub was established in 2013 to allow life science companies to take advantage of the world class facilities available at Alderley Park. Focused on attracting, creating, and scaling companies.• BioHub at Alderley Park is a thriving ecosystem of life science companies, which has successfully counteracted the potential economic consequences (estimated at c£2bn over ten years) of AstraZeneca’s relocation of its largest R&D facility to Cambridge. • In just four years, the BioHub and gained the ‘Outstanding Achievement’ award at the 2017 UK Life Science Industry awards: “…the most novel and innovative company whose technology is causing significant disruption in their field.” • In both 2016 and 2017 achieved the ‘Best UK Life Science Incubator’ for the BioHub because of “..the breadth and depth of the offering and complete support for companies…” In addition, the BioHub received the 2015 Bionow “Best Service support” award. • World class Expert Mentoring Network, including more than 200 senior global industry leaders making themselves available to SME’s on site. Now expanded nationally to Nottingham and Scotland • Lean-start-up ‘bootcamps’ deliver 2 day and 12 week programmes based upon international best practice, with content and advisory input from global thought leaders, now expanded across BioCity Group• Public and private strategic partnerships have been established to provide pipeline services and support for on-site companies: NELSA, North of England Life Science Accelerator with the N8 Research Universities; Biofilm Innovation and Knowledge Centre; OBN discounted purchasing scheme, a strategic partnership with Water Corporation ($10b Mkt cap), and corporate partnerships with professional service firms• £2.2m in grants for Research, Innovation, and Business Support• Significant role in the regional and national life science ecosystem • Lead role in establishing APV (below)

Property platform representing Asian and ME investors interested in direct relationships with UK property principals

Investment Banking, Private Placement for venture and high net worth investment in life science and technology companies and funds (closed end)

Investment Banking, Private Placement for venture and high net worth investment in life science and technology companies